The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Genomic and imaging biomarkers associated with cabozantinib therapy in metastatic castrate resistant prostate cancer (mCRPC).
 
Ulka N. Vaishampayan
Honoraria - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; Novartis; Pfizer; Sanofi
Speakers' Bureau - Astellas Pharma; Bayer; Janssen; Novartis; Pfizer
Research Funding - Astellas Pharma; Exelixis; Novartis; Pfizer
 
Izabela Podgorski
No Relationships to Disclose
 
Lance K. Heilbrun
No Relationships to Disclose
 
Daryn W. Smith
No Relationships to Disclose
 
Jawana Lawhorn-Crews
No Relationships to Disclose
 
Kimberlee Dobson
No Relationships to Disclose
 
Joseph A. Fontana
No Relationships to Disclose
 
Elisabeth I. Heath
Honoraria - Bayer; Dendreon; Sanofi
Research Funding - Agensys (Inst); Celgene (Inst); Celldex (Inst); Dendreon (Inst); Genentech/Roche (Inst); Inovio Pharmaceuticals (Inst); Millennium (Inst); Seagen (Inst); Tokai Pharmaceuticals (Inst)
 
Anthony Frank Shields
Stock and Other Ownership Interests - Radiology Corporation of America
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Endocyte; GE Healthcare; Merck; Merrimack; Perceptive Informatics; Siemens Healthcare Diagnostics; Taiho Pharmaceutical
Speakers' Bureau - GE Healthcare
Research Funding - Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Karyopharm Therapeutics; Merrimack; Novartis; OncoMed; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Endocyte; GE Healthcare; Merrimack